NASDAQ: ELVNEnliven Therapeutics Inc Stock
$21.41-0.34 (-1.56%)
Updated Oct 17, 2025
ELVN Price
$21.41
Fair Value Price
$2.64
Market Cap
$1.27B
52 Week Low
$13.30
52 Week High
$29.79
P/E
-10.71x
P/B
2.6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$100.22M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$71M
Beta
1.05
Next Earnings
Nov 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ELVN Overview
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELVN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ELVN
Ranked#304 of 481
Ranked#304 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.26 | A | |
| $6.63 | A | |
| $11.55 | A |
Be the first to know about important ELVN news, forecast changes, insider trades & much more!
ELVN News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELVN ($21.41) is overvalued by 712% relative to our estimate of its Fair Value price of $2.64 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELVN ($21.41) is not significantly undervalued (712%) relative to our estimate of its Fair Value price of $2.64 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELVN due diligence checks available for Premium users.
Valuation
ELVN fair value
Fair Value of ELVN stock based on Discounted Cash Flow (DCF)
Price
$21.41
Fair Value
$2.64
Overvalued by
712.00%
ELVN ($21.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELVN ($21.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.71x
Industry
-98.2x
Market
37.42x
ELVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.6x
Industry
4.96x
ELVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELVN's financial health
Profit margin
Revenue
$0.0
Net Income
-$25.3M
Profit Margin
0%
ELVN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$503.9M
Liabilities
$15.4M
Debt to equity
0.03
ELVN's short-term assets ($495.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELVN's short-term assets ($495.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELVN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.1M
Investing
-$183.6M
Financing
$218.4M
ELVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELVN vs Biotech Stocks
Enliven Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.